From 1 March 2023, Australians with recurrent melanoma will have a new treatment option subsidised by the Pharmaceutical Benefits Scheme (PBS).
Publications
FDA news: Breast cancer, melanoma agents win fast track, orphan drug status
The FDA announced several regulatory actions the past few weeks.
A 47-Year-Old Woman with Metastatic Melanoma
Hussein Tawbi, MD, PhD: Hello. My name is Hussein Tawbi. I’m a melanoma medical oncologist at MD Anderson Cancer Center. I’m professor and deputy chair of the Department of Melanoma Medical Oncology and co-director of the Brain Metastasis Clinic here at MD Anderson Cancer Center. What we’re discussing today is a case of an unfortunate lady in her 40s, specifically a 47-year-old lady who presented with a 2.2-millimeter primary melanoma of the skin of her left thigh.
FDA Grants Orphan Drug Designation to LNS8801 for Metastatic Cutaneous Melanoma
The FDA has granted orphan drug designation for LNS8801 for the treatment of patients with metastatic cutaneous melanoma, according to Linnaeus Therapeutics, Inc.